Ani Pharmaceuticals (ANIP) Interest & Investment Income (2010 - 2026)

Ani Pharmaceuticals has disclosed Interest & Investment Income across 17 years of filings, most recently posting -$3.8 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at -$3.8 million, up 31.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.3 million (up 0.76% YoY), and the FY2025 annual result was -$20.1 million, down 13.96% from the prior year.
• Interest & Investment Income came in at -$3.8 million for Q1 2026 at Ani Pharmaceuticals, up from -$4.4 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of -$2.3 million in Q3 2024 to a low of -$7.7 million in Q1 2023.
• The 5-year median for Interest & Investment Income is -$5.7 million (2023), against an average of -$5.7 million.
• Across the five-year window, Interest & Investment Income plunged 190.91% in 2022 and soared 63.57% in 2024, its largest moves.
• Ani Pharmaceuticals' Interest & Investment Income stood at -$7.5 million in 2022, then advanced by 23.45% to -$5.7 million in 2023, then retreated by 4.68% to -$6.0 million in 2024, then climbed by 26.67% to -$4.4 million in 2025, then rose by 14.55% to -$3.8 million in 2026.
• The last three Interest & Investment Income figures came in at -$3.8 million (Q1 2026), -$4.4 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.